With Grant Funding, Empire Advancing Potential Companion Test for Proteasome Inhibitors | GenomeWeb

Empire Genomics has discovered a genetic mutation that early studies suggest might be linked to increased response to a class of drugs called proteasome inhibitors.

If Empire can successfully develop a test that gauges this mutation and can predict which patients will respond to proteasome inhibitors, such as Velcade, such a diagnostic could help doctors personalize treatment for multiple myeloma patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.